Cholinesterase inhibitors are primarily used in the treatment of patients with mild to moderate Alzheimer's disease. Rivastigmine is a centrally selective cholinesterase inhibitor with a high selectivity for the hippocampus and cortex.([1]) A recent paper showed that in patients with Alzheimer's disease, treatment with high dosages of rivastigmine of 6-12 mg/day produced improvements in cognitive function and disease severity. [([2,3]) The most common adverse drug reactions associated with rivastigmine include nausea, vomiting and abdominal pain. These are mild to moderate, of short duration and diminish with a reduction in dosage. They commonly occur during the dosage titration phase and decrease during the maintenance phase. In this report, we present a case of melaena during therapy with rivastigmine in a patient with Alzheimer's disease.
Cholinesterase inhibitors are primarily used in the treatment of patients with mild to moderate Alzheimer's disease. Rivastigmine is a centrally selective cholinesterase inhibitor with a high selectivity for the hippocampus and cortex.([1]) A recent paper showed that in patients with Alzheimer's disease, treatment with high dosages of rivastigmine of 6-12 mg/day produced improvements in cognitive function and disease severity. [([2,3]) The most common adverse drug reactions associated with rivastigmine include nausea, vomiting and abdominal pain. These are mild to moderate, of short duration and diminish with a reduction in dosage. They commonly occur during the dosage titration phase and decrease during the maintenance phase. In this report, we present a case of melaena during therapy with rivastigmine in a patient with Alzheimer's disease.
Melaena following use of the cholinesterase inhibitor rivastigmine
Gareri P;Gallelli L;Russo E;De Sarro G
2005-01-01
Abstract
Cholinesterase inhibitors are primarily used in the treatment of patients with mild to moderate Alzheimer's disease. Rivastigmine is a centrally selective cholinesterase inhibitor with a high selectivity for the hippocampus and cortex.([1]) A recent paper showed that in patients with Alzheimer's disease, treatment with high dosages of rivastigmine of 6-12 mg/day produced improvements in cognitive function and disease severity. [([2,3]) The most common adverse drug reactions associated with rivastigmine include nausea, vomiting and abdominal pain. These are mild to moderate, of short duration and diminish with a reduction in dosage. They commonly occur during the dosage titration phase and decrease during the maintenance phase. In this report, we present a case of melaena during therapy with rivastigmine in a patient with Alzheimer's disease.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
